anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention supplies a Totelode osmosis pump type controlled release formulation, whose constitutes weight percentages are: Totelode 0.5-10.0 percent, findings for controlling release 80.0-99.0 percent and other findings. The type of this invention is osmosis pump troche. Findings for controlling release are separated to controlled release film material and controlled release osmotic pressure active compounds; the other findings contain bond, lubricant and thin film materials that usually used in troche preparation. This Totelode osmosis pump troche can keep effective medicine concentration for a day, advance curative effect and decrease side effect, and its release assumes zeroth-order characteristic in certain period. It is convenient to eat and taking, and it can cut down medicine-taking times. It can used broadly to cure urination frequent, urination urgent, precipitant urine incontinence, and so on caused by bladder pubovesical muscle excess excitation.
Lung cancer is the most lethal of all malignant tumors affecting humans. In the United States alone an estimated 160,440 patients died of lung cancer 2004\[1\]. It is well known that tobacco smoking is a major risk factor and accounts for the majority of all lung cancer cases. But there is a sub group of patients with lung cancer who have never actively smoked tobacco. This group exhibits certain unique characteristics which separates them from lung cancer in smokers. It has been shown that never- smokers with adenocarcinoma have better outcomes in terms of overall survival as well as lung cancer specific survival when compared to current smokers with adenocarcinoma of the lung\[2\]. Also patients who are current smokers at diagnosis have decreased survival when compared to people who quit smoking\[3\]. The improved survival in never smokers could be due to several reasons. Such as increased incidence of co-morbid factors in smokers as result of exposure to tobacco smoke, differences in metabolism of chemotherapeutic agents or a reflection of differences in the underlying molecular biology of the tumor.

It has been demonstrated that chromosomal abnormalities are common in lung cancer patients with a smoking history when compared to never- smokers\[4\]. Gene mutations such as p53 mutations are more frequent in never- smokers than in previous smokers\[5\]. In addition mutations that are specific only to lung cancer in never smokers have been discovered, demonstrating the possibility of a separate or overlapping carcinogenesis pathway for lung cancer in never smokers vs. smokers \[6\].
OBJECTIVE: To systematically review the methodology, performance, and generalizability of diagnostic models for predicting the risk of healthcare-facility-onset (HO) Clostridioides difficile infection (CDI) in adult hospital inpatients (aged ≥18 years).
BACKGROUND: CDI is the most common cause of healthcare-associated diarrhea. Prediction models that identify inpatients at risk of HO-CDI have been published; however, the quality and utility of these models remain uncertain.
METHODS: Two independent reviewers evaluated articles describing the development and/or validation of multivariable HO-CDI diagnostic models in an inpatient setting. All publication dates, languages, and study designs were considered. Model details (eg, sample size and source, outcome, and performance) were extracted from the selected studies based on the CHARMS checklist. The risk of bias was further assessed using PROBAST.
RESULTS: Of the 3,030 records evaluated, 11 were eligible for final analysis, which described 12 diagnostic models. Most studies clearly identified the predictors and outcomes but did not report how missing data were handled. The most frequent predictors across all models were advanced age, receipt of high-risk antibiotics, history of hospitalization, and history of CDI. All studies reported the area under the receiver operating characteristic curve (AUROC) as a measure of discriminatory ability. However, only 3 studies reported the model calibration results, and only 2 studies were externally validated. All of the studies had a high risk of bias.
CONCLUSION: The studies varied in their ability to predict the risk of HO-CDI. Future models will benefit from the validation on a prospective external cohort to maximize external validity.
This pilot study will evaluate the feasibility, acceptability, and potential effectiveness of the Step Up Wellness Program among people with depression who also are physically inactive and smoke cigarettes.

Participation in this study will last 6 months. All participants will complete a baseline survey and then be assigned randomly to receive the Step Up Wellness Program or usual care for 3 months. Participants in the Step Up program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking. Participants will also be given materials to review and homework assignments between calls. Participants in the usual care group will receive standard care which includes referrals for treatment of depression and nicotine dependence, as well as self-help information on physical activity. All participants will be surveyed at 4 and 6 months post-enrollment. Participants will also provide qualitative feedback on the program.
PURPOSE:To obtain a hair dye having excellent safety and dyeing property and free from the skin-staining problem by compounding an acid dye and a cellulose ether containing quaternary nitrogen. CONSTITUTION:The objective hair dye contains 0.01-10wt.% of an acid dye, 0.01-10wt.% of a cellulose ether containing quaternary nitrogen and, as necessary, 1-40wt.% of a dyeing assistant. It is further compounded properly with conventional additives for hair dye, e.g. surfactant, viscosity modifier, pH modifier, UV absorber, sequestering agent and perfumery and used in the form of liquid, powder, cream, paste, gel, aerosol, foam, etc. The cellulose ether containing quaternary nitrogen is e.g. Polymer JR-125 (product of Union Carbide) produced by the reaction of hydroxyethyl cellulose and glycidyl trimethyl ammonium chloride.
OBJECTIVE: We hypothesized that combination therapy would provide a synergistic effect to improve treatment outcomes for overactive bladder (OAB), thus enhancing the motivation for continuous exercise, and that it would be associated with fewer adverse events than monotherapy. Therefore, we investigated whether biofeedback-assisted pelvic floor muscle training (PFMT), drug therapy, or a combination of both would be more effective in improving the symptoms of OAB.
STUDY DESIGN: This randomized controlled trial included women diagnosed with OAB. Group 1 received biofeedback-assisted pelvic muscle floor training (PFMT) for 12 weeks; group 2 took 5 mg of solifenacin/day for 12 weeks; and group 3 received 5 mg of solifenacin/day in combination with biofeedback-assisted PFMT during the first 4 weeks and biofeedback-assisted PFMT for another 8 weeks. All participants had 5 follow-up visits. The primary outcomes were objective improvement of OAB symptoms and quality of life. The secondary outcomes were treatment-related adverse events, subjective improvement of OAB symptoms, and electromyographic activity of pelvic floor muscle (PFM) contraction.
RESULTS: All participants reported significant improvement of OAB symptoms and quality of life. Participants in group 2 experienced more pronounced adverse events than those in group 3. Intervention duration was positively associated with subjective improvement in OAB symptoms in groups 2 and 3. Drug-related adverse events, including dry mouth, myalgia, and restlessness, had a negative impact on the subjective improvement of OAB symptoms in group 2. In group 1, exercise adherence was positively correlated with subjective improvement of OAB symptoms, whereas in group 3, PFM contraction and biofeedback effect were positively correlated with symptom improvement.
CONCLUSION: Combination therapy is efficacious in treating women with OAB.
Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
A complex craniofacial wound is a wound on the head or face that will not heal, despite efforts to heal the wound with standard treatments, such as antibiotics and surgery to clean the wound. Currently, there are no good treatment options for these types of complex craniofacial wounds. This study will evaluate what happens when free dermal fat autografting is used to help treat complex craniofacial wounds by evaluating the area where the graft was placed to better understand how these types of grafts function. Free dermal fat autografting is the process of taking fat from under the outer layer of skin and moving it to another part of the body of the same individual. Although free dermal fat autografts have been used for many decades in plastic and reconstructive surgery to help a variety of patients suffering from different problems, only one study has used them to help heal complex craniofacial wounds. This use of free dermal fat autografting is not considered to be experimental or an investigational product by the US Food and Drug Administration (FDA). Still, the use of free dermal fat autografting has not been formally evaluated to understand how these types of grafts help patients with complex craniofacial wounds.
PURPOSE:An inexpensive pack suitable for packing the face or the whole body, comprising natural or synthetic clay mineral powder, rubber-like material of polysaccharide or synthetic paste powder and cellulose powder as essential components. CONSTITUTION:A pack comprising 100pts.wt. natural or synthetic clay mineral powder (e.g., kaolin, bentonite, acid clay, diatomaceous earth, or talc), 10-20pts. wt. rubber-like material of polysaccharide or synthetic paste powder (gum arabic powder, or sodium carboxymethyl cellulose), 30-70pts.wt. celluose powder (e.g., crystallite cellulose powder), and various kinds of crude drugs, extract powder, medicines, medicinal mineral powder, purified oil, fatty acid ester, glycols, perfume, preservative, coloring matter, etc. as additional components. This pack is distributed to consumers in the state of powder, and, when it is mixed with water or an oil, it is instantly made into a uniform muddy state without forming undissolved parts of the components.
Living cells are modified at their surface with specially selected polymers. Covalently attaching specially selected polyethylene glycol (PEG) derivatives to the surface of red blood cells (RBC) in aqueous media under mild conditions is a preferred example. The selected PEG derivatives dramatically reduced aggregation and low shear viscosity of RBC resuspended in autologous plasma, and inhibited RBC agglutination by blood group-specific antibodies. The morphology and deformability of the PEG-treated cells were unaltered. PEG coating of the RBC surface is applicable to the treatment of a variety of diseases characterized by vaso-occlusion or impaired blood flow, e.g., myocardial infarction, shock, and sickle cell disease. An infusion solution is prepared containing red blood cells covalently bound to a PEG derivative having a molecular weight of between 2,000 and 5,000 Daltons and a PEG derivative having a molecular weight between 10,000 and 35,000 Daltons.
This study is a cluster randomized trial (CRT) where the hospitals are the clusters. 44 hospitals in Germany have confirmed their participation. Hospitals are randomized into two groups: a control and an interventional group. The control group receives conventional CMEs. The interventional group receives tools for increasing awareness such as posters and brochures. Quality measure such as benchmarking and feedback of quality indicators are used. Depending on the improvement process tools such as SWOT analyses and resistance radar will be implemented.

The CRT was preceded by a 5 months observational study (Dec. 2010 - April 2011). In about 1000 patients, participating hospitals documented their patients with severe sepsis or septic shock into a register. These data are used for final sample size calculation of the CRT and for stratification of the randomization.

The groups switch after completion of the CRT and observation continues. Thus, centers of the control group now receive the change management while the former intervention group is now without external support and is assessed for sustainability of the intervention. This study phase is planned for Nov. 2013 until March 2015. Sample size will be calculated when the CRT has been finished.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and can be used for administering the preparation in the tissues of the external auditory canal in treating patients with tissue hypertrophy in the medial portion of the external auditory canal. That is ensured by conducting the needle through the lumen of the external auditory canal and administering the solution in the form of injections. Needle is passed through a lumen of the external auditory canal to its medial part. Insertion of the needle is started in the direction from the anterior meatotympanic angle to the posterior meatotympanic angle. Injections are performed directly into hypertrophic tissue by immersing whole needle section therein. Solution is introduced into the hypertrophic tissue by parts – by injections performed at a distance no closer than 3 mm from each prick-in point, creating a drug depot directly in the hypertrophic tissue.EFFECT: method provides higher clinical effectiveness with reduced dose of the administered preparation, increased time of its resorption from the depot created, as well as reduced traumatism of the procedure and enables avoiding disturbed microcirculation when introducing the solutions.1 cl, 3 dwg, 1 ex
<P>PROBLEM TO BE SOLVED: To provide a dried gel material which improves swallowing of an oral medicine and suitable for masking the oral medicine having an unpleasant flavor, to provide the oral medicine comprising the dried material, and to provide an inexpensive and simple method for preparing the medicine.  <P>SOLUTION: The dried gel material is prepared by drying a gel-like material prepared by mixing a positively chargeable polyelectrolyte with a negatively chargeable polyelectrolyte. The mixture comprises the dried material and an active ingredient of the medicine or an additive of the medicine. The oral medicine is prepared from the mixture. The method for preparing the oral medicine comprises mixing the positively chargeable polyelectrolyte with the negatively chargeable polyelectrolyte and the active ingredient of the medicine or the additive of the medicine, affording the gel-like material and drying the resultant gel-like material or mixing the positively chargeable polyelectrolyte with the negatively chargeable polyelectrolyte, affording the gel-like material, drying the gel-like material, adding a solution or a suspension of the active ingredient of the medicine or a solution or a suspension of the additive of the medicine to the dried gel material, carrying out swelling and gelation and drying the gel.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The waitlist control group will not receive any active intervention until after completing week 12 and week 26 assessments. Participants will receive periodical updates and reminders from study staff to enhance retention. After assessments are completed, participants will be provided with 12 weeks of the Healing HEARTS intervention.
This study will characterize the neurochemical abnormalities in important brain circuits underlying obsessive-compulsive disorder (OCD) symptoms and the effects of cognitive-behavioral therapy (CBT). Identification of such metabolite biomarkers will provide an important foundation for translational clinical studies to maximize the ability of CBT to reduce symptoms and to design medications that target core features of the disease, which is particularly important for those who do not respond to, or have access to, CBT.

OCD is an often disabling and chronic psychiatric condition that affects approximately 2% of the world's population. Most patients respond only incompletely to current treatments and many do not respond at all. CBT, a form of psychotherapy, is one of the most effective treatments for OCD, yet its mechanism of action is not fully understood. The objective of this study is to use neuroimaging to understand how neurometabolite abnormalities in neural circuits relate to OCD symptoms, and how these are affected by CBT. In OCD, dysfunction is suspected in several subregions of the cingulate gyrus, a brain region involved in relevant neural circuits. This study will use magnetic resonance spectroscopic imaging (MRSI) to measure concentrations of brain metabolites, including glutamate (Glu), in the cingulate. Glu is an important excitatory neurotransmitter that is suspected to be disturbed in OCD. In this study, MRSI scans will be performed on 25 adult OCD patients before and after 4 weeks of daily CBT. They will be compared to 25 untreated healthy controls scanned 4 weeks apart. A third group of 25 OCD patients will be scanned before and after 4 weeks while on the waitlist, will then receive 4 weeks of CBT, and will be scanned a third time at its completion. The specific aims of this study are: 1) Determine if levels of the Glu in the "emotional" and "cognitive" subregions of the cingulate differ between OCD patients and controls; 2) Determine if Glu changes after CBT or waitlist in the OCD patients and if they change in the controls after simple passage of time; 3) Determine if there are relationships between Glu and clinical and neurocognitive symptoms of OCD before and after CBT.
Morning Session \[11C\]raclopride PET scan: To be started between 7-8 AM. After iv catheters are inserted, genetic blood samples are drawn and then blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plusinfusion method for \[11C\]raclopride and the administration of intravenous MP (0.25 mg/kg) fortyfive minutes after initial bolus injection of \[11C\]raclopride. Scan to be done for a total of 100 minutes.
All participants in the teen video phase of this project will make brief videos about living well with type 1 diabetes. Guidance will be provided about requirements for the videos. Participants may make up to 4 brief videos. The videos will be used in the upcoming clinical trial of the new behavioral intervention.
Molecular cloning and expression of a human gene encoding a polypeptide activator of proteasomes is disclosed. The expressed activator has an Mr of about 29,000 and is functional in activating proteasomes in vitro. In vivo this activator polypeptide is inducible with  gamma -interferon in HeLa cells and occurs with a non- gamma -interferon-inducible polypeptide with an Mr of about 31,000 in a hexameric activator complex. The activator protein contains a lysine and glutamate rich region termed a KEKE motif. The KEKE motif appears to promote association between proteins and selection of peptides for presentation on MHC Class I receptors. A method for enhancing cell-mediated immunity against or tolerance to a selected immunogenic peptide is described comprising expressing activator and the selected peptide, wherein the selected peptide is adjacent to a KEKE motif, in an appropriate cell.
Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
Patients with a history of severe COVID-19 infection (confirmed by a polymerase chain reaction test) requiring mechanical ventilation. This group includes patients who have been recently diagnosed with stable angina and have previously experienced a severe COVID-19 infection that necessitated mechanical ventilation support during their illness.
Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
Protaper Next group (n=25): The instrumentation of mesial and distal canals were done according to manufacturer's recommendations using X1 and X2 (25.06) at a rotational speed of 300 rpm. Then X3 and X4 (40.06) instruments were used to enlarge distal canals in order to compare the results with the Reciproc Blue group. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
INTRODUCTION: PIGW-related glycosylphosphatidylinositol deficiency is a rare disease that manifests heterogeneous clinical phenotypes.
METHODS: We describe a patient with PIGW deficiency and summarize the clinical characteristics of the case. In addition, we conducted a literature review of previously reported patients with pathogenic variants of PIGW.
RESULTS: A Chinese girl presented with refractory epilepsy, severe intellectual disability, recurrent respiratory infections, and hyperphosphatasia. Seizures worsened during fever and infections, making her more susceptible to epileptic status. She was found to carry a heterozygous variant of PIGW and a deletion of chromosome 17q12 containing PIGW. Only six patients with homozygous or compound heterozygous pathogenic variants of PIGW have been identified in the literature thus far. Epileptic seizures were reported in all patients, and the most common types of seizures were epileptic spasms. Distinctive facial and physical features and recurrent respiratory infections are common in these patients with developmental delays. Serum alkaline phosphatase (ALP) levels were elevated in four of the six patients.
CONCLUSIONS: PIGW-related glycosylphosphatidylinositol deficiency is characterized by developmental delay, epilepsy, distinctive facial features, and multiple organ anomalies. Genetic testing is an important method for diagnosing this disease, and flow cytometry and serum ALP level detection are crucial complements for genetic testing.